Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder

Molecular and Cellular Biology

Volumn 20, Issue 4, 2000, Pages 1149-1161

  Hao, Sheryl X ^a   Ren, Ruibao ^a  

^a BRANDEIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; DYNAMIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BONE MARROW; BONE MARROW CELL; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; HEMATOPOIESIS; LYMPHOCYTE PROLIFERATION; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; B-LYMPHOCYTES; BASE SEQUENCE; BONE MARROW TRANSPLANTATION; COLONY-FORMING UNITS ASSAY; CONSENSUS SEQUENCE; DISEASE MODELS, ANIMAL; DNA PRIMERS; DOWN-REGULATION; FLUOROURACIL; GENES, ABL; HEMATOPOIESIS; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICE; MICE, INBRED BALB C; MYELOPROLIFERATIVE DISORDERS; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC;

ANIMALIA; MURINAE;

EID: 0033956688     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.20.4.1149-1161.2000     Document Type: Article

References (45)

1. Abelson, H. T., and L. S. Rabstein. 1970. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 30:2213-2222.
2. Bhatia, R., E. A. Wayner, P. B. McGlave, and C. M. Verfaillie. 1994 Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function. J. Clin. Investig. 94:384-391.
3. Bovolenta, C., P. H. Driggers, M. S. Marks, J. A. Medin, A. D. Politis, S. N. Vogel, D. E. Levy, K. Sakaguchi, E. Appella, J. E. Coligan, et al. 1994. Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc. Natl. Acad. Sci. USA 91:5046-5050.
4. Coligan, J. E., A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.). 1996. Current protocols in immunology. John Wiley & Sons, Inc., New York, N.Y.
5. Daley, G. Q., R. A. Van Etten, and D. Baltimore. 1990. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 247:824-830.
6. Driggers, P. H., D. L. Ennist, S. L. Gleason, W. H. Mak, M. S. Marks, B. Z. Levi, J. R. Flanagan, E. Appella, and K. Ozato. 1990. An interferon gamma-regulated protein that binds the interferon- inducible enhancer element of major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. USA 87:3743-3747.
7. Eisenbeis, C. F., H. Singh, and U. Storb. 1995. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev. 9:1377-1387.
8. Eklund, E. A., A. Jalava, and R. Kakar. 1998. PU.1, interferon regulatory factor 1, and interferon consensus sequence- binding protein cooperate to increase gp91(phox) expression. J. Biol. Chem. 273;13957-13965.
9. Elefanty, A. G., I. K. Hariharan, and S. Cory. 1990. bcr-abl. the hallmark of chronic myeloid leukemia in man, induces multiple hematopoietic neoplasms in mice. EMBO J. 9:1069-1078.
10. Fisher, R. C., and E. W. Scott. 1998. Role of PU.1 in hematopoiesis. Stem Cells 16:25-37.
11. Giese, N. A., L. Gabriele, T. M. Doherty, D. M. Klinman, L. Tadesse-Heath, C. Contursi, S. L. Epstein, and H. C. Morse III. 1997. Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J. Exp. Med. 186:1535-1546.
12. Gross, A. W., X. Zhang, and R. Ren. 1999. Bcr-Abl with an SH3 deletion retains the ability to induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy. Mol. Cell. Biol. 19:6918-6928.
13. Harada, H., T. Taniguchi, and N. Tanaka. 1998. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie 80:641-650.
14. Hawley, R. G., F. H. L. Lieu, A. Z. C. Fong, and T. S. Hawley. 1995. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1:136-138.
15. Heisterkamp, N., G. Jenster, J. ten Hoeve, D. Zovich, P. K. Pattengale, and J. Groffen. 1990. Acute leukemia in bcr/abl transgenic mice. Nature 344:251-253.
16. Holtschke, T., J. Lohler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K. P. Knobeloch, L. Gabriele, J. F. Waring, M. F. Bachmann, R. M. Zinkernagel, H.C. Morse III, K. Ozato, and I. Horak. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307-317.
17. Honda, H., T. Fujii, M. Takatoku, H. Mano, O. N. Witte, Y. Yazaki, and H. Hirai. 1995. Expression of p210bcr-abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood 85:2853-2861.
18. Honda, H., H. Oda, T. Suzuki, T. Takahashi, O. N. Witte, K. Ozawa, T. Ishikawa, Y. Yazaki, and H. Hirai. 1998. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood 91:2067-2075.
19. Kelliher, M. A., J. McLaughlin, O. N. Witte, and N. Rosenberg. 1990. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87:6649-6653.
20. Kelliher, M. A., D. J. Weckstein, A. G. Knott, H. H. Wortis, and N. Rosenberg. 1993. ABL oncogenes directly stimulate two distinct target cells in bone marrow from 5-fluorouracil-treated mice. Oncogene 8:1249-1256.
21. Kurzrock, R., J. Gutterman, and M. Talpaz. 1988. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 319:990-998.
22. Li, S., R. L. Ilaria, R. P. Million, G. Q. Daley, and R. A. Van Etten. 1999. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 189:1399-1412.
23. Magram, J., J. Sfarra, S. Connaughton, D. Faherty, R. Warrier, D. Carvajal, C. Y. Wu, C. Stewart, U. Sarmiento, and M. K. Gately. 1996. IL-12-deficient mice are defective but not devoid of type 1 cytokine responses. Ann. N. Y. Acad. Sci. 795:60-70.
24. Melo, J. V. 1996. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype. Blood 88:2375-2384.
25. Nelson, N., Y. Kanno, C. Hong, C. Contursi, T. Fujita, B. J. Fowlkes, E. O'Connell, J. Hu-Li, W. E. Paul, D. Jankovic, A. F. Sher, J. E. Coligan, A. Thornton, E. Appella, Y. Yang, and K. Ozato. 1996. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J. Immunol. 156:3711-3720.
26. Nelson, N., M. S. Marks, P. H. Driggers, and K. Ozato. 1993. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol. Cell. Biol. 13:588-599.
27. Nguyen, H., J. Hiscott, and P. M. Pitha. 1998. The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 8:293-312.
28. Pear, W. S., J. P. Miller, L. Xu, J. C. Pui, B. Suffer, R. C. Quackenbush, A. M. Pendergast, R. Bronson, J. C. Aster, M. L. Scott, and D. Baltimore. 1998. Efficient and rapid induction of a chronic myclogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-3792.
29. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
30. Peschel, C., W. E. Aulitzky, and C. Huber. 1996. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment - impact on treatment of myeloproliferative disorders. Leuk Lymphoma 22(Suppl. 1):129-134.
31. Pfeffer, L. M., C. A. Dinarello, R. B. Herberman, B. R. G. William, E. C. Borden, R. Bordens, M. R. Walter, T. L. Nagabhushan, P. P. Trotta, and S. Pestka. 1998. Biological properties of recombinant alpha-interferon: 40th anniversary of the discovery of interferons. Cancer Res. 58:2489-2499.
32. Politis, A. D., K. Ozato, J. E. Coligan, and S. N. Vogel. 1994. Regulation of IFN-gamma-induced nuclear expression of IFN consensus sequence binding protein in murine peritoneal macrophages. J. Immunol. 152:2270-2278.
33. Politis, A. D., J. Sivo, P. H. Driggers, K. Ozato, and S. N. Vogel. 1992. Modulation of interferon consensus sequence binding protein mRNA in murine peritoneal macrophages. Induction by IFN-gamma and down-regulation bv IFN-alpha, dexamethasone, and protein kinase inhibitors. J. Immunol. 148:801-807.
34. Ren, R., Z. Ye, and D. Baltimore. 1994. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev. 8:783-795.
35. Rosenberg, N., and D. Baltimore. 1976. A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J. Exp. Med. 143:1453-1463.
36. Scharton-Kersten, T., C. Contursi, A. Masumi, A. Sher, and K. Ozato. 1997. Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J. Exp. Med. 186:1523-1534.
37. Schmidt, M., S. Nagel, J. Proba, C. Thiede, M. Ritter, J. F. Waring, F. Rosenbauer, D. Huhn, B. Wittig, I. Horak, and A. Neubauer. 1998. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91:22-29.
38. Selleri, C., T. Sato, L. Del Vecchio, L. Luciano, A. J. Barrett, B. Rotoli, N. S. Young, and J. P. Maciejewski. 1997. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89:957-964.
39. Sharf, R., D. Meraro, A. Azriel, A. M. Thornton, K. Ozato, E. F. Petricoin, A. C. Lamer, F. Schaper, H. Hauser, and B. Z. Levi. 1997. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J. Biol. Chem. 272:9785-9792.
40. Talpaz, M. 1994. Use of interferons in the treatment of chronic myeloid leukemia. Semin. Oncol. 21(Suppl. 14):3-7.
41. Voncken, J. W., V. Kaartinen, P. K. Pattengale, W. T. Germeraad, J. Groffen, and N. Heisterkamp. 1995. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood 86:4603-4611.
42. Weisz, A., S. Kirchhoff, and B. Z. Levi. 1994. IFN consensus sequence binding protein (ICSBP) is a conditional repressor of IFN inducible promoters. Int. Immunol. 6:1125-1131.
43. Weisz, A., P. Marx, R. Sharf, E. Appella, P. H. Driggers, K. Ozato, and B. Z. Levi. 1992. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J. Biol. Chem. 267:25589-25596.
44. Wu, C. Y., H. Maeda, C. Contursi, K. Ozato, and R. A. Seder. 1999. Differential requirement of IFN consensus sequence binding protein for the production of IL-12 and induction of Th1-type cells in response to IFN-gamma. J. Immunol. 162:807-812.
45. Zhang, X., and R. Ren. 1998. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92:3829-3940.